Articles tagged with: SEA-BCMA
Press Releases»
- SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma
- Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors
Bothell, WA (Press Release) – Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM). SEA-BCMA is an investigational antibody empowered using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody dependent cellular cytotoxicity. …